Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019

Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapi...

Full description

Saved in:
Bibliographic Details
Published inJournal of the National Comprehensive Cancer Network Vol. 17; no. 5; p. 414
Main Authors Brown, Patrick A, Wieduwilt, Matthew, Logan, Aaron, DeAngelo, Daniel J, Wang, Eunice S, Fathi, Amir, Cassaday, Ryan D, Litzow, Mark, Advani, Anjali, Aoun, Patricia, Bhatnagar, Bhavana, Boyer, Michael W, Bryan, Teresa, Burke, Patrick W, Coccia, Peter F, Coutre, Steven E, Jain, Nitin, Kirby, Suzanne, Liu, Arthur, Massaro, Stephanie, Mattison, Ryan J, Oluwole, Olalekan, Papadantonakis, Nikolaos, Park, Jae, Rubnitz, Jeffrey E, Uy, Geoffrey L, Gregory, Kristina M, Ogba, Ndiya, Shah, Bijal
Format Journal Article
LanguageEnglish
Published United States 01.05.2019
Online AccessGet more information

Cover

More Information
Summary:Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.
ISSN:1540-1413
DOI:10.6004/jnccn.2019.0024